Enzon Pharmaceuticals, Inc.

ENZN

US2939041081

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:37:14 17/05/2024 BST			5-day change	1st Jan Change
0.0949 ^USD	+7.11%		+9.33%	+1.39%

05-10	Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-20	Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Enzon Pharmaceuticals, Inc. Provides Information to the Shareholders

August 10, 2020 at 11:56 am

On August 10, 2020, Enzon Pharmaceuticals, Inc. announced that on August 4, 2020, the Company appointed Jordan Bleznick as a director, who is an employee of Icahn Enterprises L.P.

Latest news about Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07/08/23	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	05/05/23	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	16/02/23	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/11/22	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	04/08/22	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/04/22	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	25/02/22	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	05/11/21	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	05/08/21	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	04/05/21	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	23/02/21	CI
Enzon Pharmaceuticals, Inc. Announces Executive Changes	04/01/21	CI
Enzon Pharmaceuticals, Inc. Appoints Richard L. Feinstein as Secretary	04/01/21	CI
Declaration of Voting Results Enzon Pharmaceuticals	21/12/20	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	09/11/20	CI
Enzon Pharmaceuticals Solicits Proxies from the Shareholders	03/11/20	CI
Enzon Pharmaceuticals to Seek Acquisition Opportunities	22/10/20	CI
Enzon Pharmaceuticals, Inc. Provides Information to the Shareholders	10/08/20	CI
Enzon Pharmaceuticals, Inc. Announces Board Changes	07/08/20	CI
Jonathan Couchman Nominates Candidates to the Board of Enzon Pharmaceuticals	05/08/20	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	29/07/20	CI
Enzon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	30/04/20	CI

Chart Enzon Pharmaceuticals, Inc.

Duration

Period

More charts

Enzon Pharmaceuticals, Inc. (Enzon) is an acquisition vehicle company. The Company intends to become an acquisition platform. The Company utilizes its net operating loss carryforwards (NOLs) and improves stockholder value. It manages its source of royalty revenues from existing licensing arrangements with other companies.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ENZON PHARMACEUTICALS, INC.	+1.39%	6.58M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B